Biochemical modulation therapy for pancreatic cancer

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Advanced pancreatic cancer typically shows limited response to conventional chemotherapy and radiotherapy.
• Emerging chemotherapy regimens, like 5-fluorouracil (5-FU) and cisplatin (CDDP), show synergistic antitumor activity in adenocarcinomas.
• Pharmacodynamic studies have established optimal drug concentrations and effects in gastrointestinal cancers.

Purpose of the Study:

• To evaluate the efficacy of a combination chemotherapy regimen using 5-FU and CDDP in patients with advanced pancreatic cancer (stage IV).
• To assess the impact of this treatment on tumor size in unresectable cases and prognosis in resectable cases.

Main Methods:

• Retrospective analysis of treatment outcomes in advanced pancreatic cancer patients receiving 5-FU and CDDP combination therapy.
• Evaluation of antitumor effects, including tumor size reduction and survival prognosis.
• Assessment of treatment-related adverse effects and impact on quality of life.

Main Results:

• The 5-FU and CDDP combination demonstrated significant antitumor effects in advanced pancreatic cancer.
• Positive outcomes were observed in tumor size reduction for unresectable patients and improved prognosis for resectable patients.
• Results were particularly notable in patients with stage IVb and curability C disease.
• Adverse effects were generally mild and did not severely compromise patient quality of life.

Conclusions:

• The combination of 5-FU and CDDP is a potentially useful treatment for advanced pancreatic cancer, offering clinical benefits.
• Further randomized prospective studies are warranted to confirm these findings and optimize treatment strategies.
• Minimizing adverse effects to preserve patient quality of life remains a critical consideration.